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IL-6 Signaling Pathway in Keloids: 
A Target for Pharmacologic 
Intervention?
Jouni Uitto1
Keloids are cosmetically devastating lesions with considerable morbidity. 
Ghazizadeh et al. document enhanced expression of IL-6 and its receptors in 
keloid fibroblasts, with a concomitant increase in collagen biosynthesis. Anti-
IL-6 antibodies or blocking the IL-6 receptors elicits reduced collagen synthesis, 
suggesting a role for IL-6 in the regulation of collagen gene expression. These 
observations imply the feasibility of a pharmacologic platform, based on the tar-
geting of the IL-6 signaling pathway, in keloids.
Journal of Investigative Dermatology (2007) 127, 6–8. doi:10.1038/sj.jid.5700604
Fibrotic skin diseases, a diverse group 
of phenotypically distinct cutaneous 
disorders, are clinically character-
ized by thickening of the skin due to 
accumulation of extracellular matrix 
of connective tissue (Uitto and Kouba, 
2000). A prototype of fibrotic skin dis-
eases is keloids, localized lesions of 
considerable cosmetic concern asso-
ciated with significant morbidity in 
terms of inflammation, infections, pru-
ritus, and pigmentary alterations. The 
primary cause of keloids is currently 
unknown, but their development is 
clearly associated with trauma to the 
skin predicated on genetic predispo-
sition of the susceptible individuals. 
Keloids are frequently encountered in 
individuals of African ancestry or of 
Asian origin, but keloid-like lesions 
are also present in white individuals, 
often demonstrating autosomal domi-
nant inheritance with incomplete pen-
etrance. The genetic basis of keloid 
formation has also been explored by 
genome-wide linkage analyses, which 
have suggested the presence of suscep-
tibility loci on chromosomal regions 
2q23 and 7p11 in a Japanese and an 
African-American family, respectively 
(Marneros et al., 2004). The observed 
locus heterogeneity may well reflect 
the phenotypic heterogeneity and 
spectrum of severity of this disease. A 
plethora of treatment modalities has 
been proposed and tested in keloids, 
apparently reflecting the fact that no 
approach is singularly superb, and 
recurrence rates are substantial after 
treatment attempts. Thus, keloids rep-
resent a major clinical challenge with 
unmet needs for therapeutic interven-
tion that could be addressed with the 
use of novel approaches.
A characteristic hallmark of keloids 
is excessive accumulation of collagen, 
primarily types I and VI, associated 
with deposition of other extracellular 
matrix components, such as fibronec-
tin (Abergel et al., 1985; Peltonen et 
al., 1991). As schematically depicted 
in Figure 1, collagen accumulation 
could result from either increased bio-
synthesis or decreased degradation, 
and currently a number of modula-
tor molecules interfering with both 
synthetic and degradative pathways 
of collagen metabolism in fibroblasts 
have been recognized (Mauviel and 
Uitto, 1993). The preponderance of 
evidence suggests that in keloids, 
increased biosynthesis is responsible 
for collagen accumulation, although 
abnormalities in the degradative 
pathways mediated by matrix metal-
loproteinases and in their inhibitors, 
tissue inhibitors of metalloprotein-
ase (TIMPs), have also been invoked 
(Uitto et al., 1985). Consistent with 
the increased rate of collagen biosyn-
thesis, transforming growth factor-β, a 
potent profibrotic cytokine, has been 
shown to be abundantly present in 
keloid connective tissues, both in peri-
vascular location and in association 
with activated fibroblasts (Peltonen et 
al., 1991). Thus, cytokines, particularly 
profibrotic molecules such as trans-
forming growth factor-β, in relation to 
its antagonists, IFN-γ and tumor necro-
sis factor-α, have been postulated to 
play a role in growth and development 
of keloid lesions.
Ghazizadeh et al. (2007) report on 
their studies exploring the pathomech-
anisms of keloids with a focus on the 
IL-6 signaling pathway. Their investi-
gations were initially directed at this 
particular cytokine by previous dem-
onstrations that IL-6 expression is 
increased in keloid fibroblast cultures 
(Xu et al., 2000) and that IL-6 induces 
collagen synthesis in fibroblasts 
(Duncan and Berman, 1991). As a fol-
low-up, these investigators compared 
early-passage fibroblast cultures estab-
lished from keloid lesions (KF) and from 
non-lesional skin (NF) in regard to the 
IL-6 pathway. The KF cells demonstrat-
ed a number of differences in compari-
son with NFs, including significantly 
increased growth rate, and upregula-
tion of IL-6 and its receptors (IL-6Rα 
and IL-6Rβ). The mean IL-6 secretion 
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 There is a role 
for IL-6 and its 
receptor-mediated 
signaling pathway 
in the accumulation 
of collagen and 
the phenotypic 
development of keloids.
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levels in KFs were elevated approxi-
mately sixfold on average. In addition 
to IL-6 and its receptors, expression of 
a number of downstream target mol-
ecules, including JAK1, STAT3, RAF1, 
and ELK1, was markedly elevated in 
KF cells as determined by semiquan-
titative reverse transcription–PCR and 
by Western blot analyses. In accor-
dance with the latter findings, the same 
downstream target molecules were 
expressed in most keloid lesions tested 
by immunohistochemistry, but the acti-
vation/phosphorylation status of these 
molecules in keloid lesions in vivo was 
not determined. Finally, the authors 
examined the functionality of IL-6 
expression by adding recombinant IL-6 
protein to cell culture or by antagoniz-
ing IL-6 or blocking its receptor with 
antibodies and using type I collagen 
biosynthesis as readout. Addition of 
IL-6 to NF cultures resulted in a signifi-
cant dose-dependent increase, whereas 
incubation of KF cultures with anti-IL-
6 or anti-IL-6Rα antibodies decreased 
the synthesis of type I collagen.
Collectively, the observations 
reported by Ghazizadeh et al. (2007) 
suggest there is a role for IL-6 and its 
receptor-mediated signaling path-
way in the accumulation of collagen 
and the phenotypic development of 
keloids. The pathomechanistic impli-
cations of their findings are somewhat 
unclear, however, for several reasons. 
Specifically, it is unclear, from the pres-
ent studies, which of the many signal-
ing pathways, including those of JAK/
STAT3 and ERK/MAP kinase, is mecha-
nistically responsible for enhanced 
collagen production in response to IL-
6/receptor activation. Thus, it may well 
be that activation of these signal trans-
action pathways, noted in KF but not 
in NF cells, results in phenotypic man-
ifestations other than changes in colla-
gen production, such as the enhanced 
cell proliferation noted in lesional 
fibroblast cultures. In fact, precise dis-
section of the signal transduction path-
ways could potentially provide novel 
insights into the regulation of collagen 
gene expression in dermal fibroblasts, 
with pharmacologic implications.
So, what are the implications of 
the results of this study for treatment 
and patient care? In other words, are 
there approaches, based on the cur-
rent findings, that can be offered to 
the patients suffering from this dev-
astating, often life-altering condition? 
The answer is: apparently not yet. 
However, identification of IL-6 signal-
ing as a critical pathway contributing 
to collagen accumulation and keloid 
formation potentially offers novel 
possibilities for pharmacologic inter-
vention. For example, development 
of specific antibodies that antago-
nize IL-6 or block its receptor could 
result in reduced collagen accumu-
lation, predicated on the results of 
this study. Similarly, development of 
peptide antagonists or receptor decoy 
molecules based on molecular mod-
eling of the receptor–ligand binding 
characteristics could potentially be 
used for the same purpose. Another 
approach would be to screen for small 
molecules, potentially identifying 
compounds that antagonize the IL-6 
receptor and its downstream signal-
ing. The potential problems with these 
approaches are somewhat generic to 
these classes of molecules and relate 
to delivery, efficacy, and specificity. 
For example, how effectively would 
topically applied antibodies diffuse to 
keloids consisting of compact collagen 
fibers, so as to reach the cell-surface 
molecules in the center of these fibrot-
ic lesions? What effective concentra-
tions are required to elicit biologically 
and clinically meaningful inhibition 
of collagen biosynthesis? What is 
the specificity of these contemplated 
approaches with respect to cell biol-
ogy in general and collagen biosyn-
thesis in particular? In this context, 
it should be noted that IL-6 has been 
implicated in a number of biological 
processes, as attested by reduced re-
epithelialization, angiogenesis, and 
impaired wound healing in transgenic 
IL-6-deficient mice (Gallucci et al., 
2000; Lin et al., 2003). Thus, inhibi-
tion of the IL-6 signaling pathway may 
have a number of effects, unrelated to 
collagen biosynthesis. These potential 
obstacles notwithstanding, the find-
ings articulated by Ghazizadeh et al. 
(2007) warrant further exploration 
of the IL-6 signaling pathway as a 
potential pharmacologic target toward 
development of novel management 
strategies for this devastating, current-
ly intractable disease.







Figure 1. Schematic representation of pathways potentially resulting in accumulation of collagen in 
fibrotic skin diseases. The net deposition of collagen is a balance between the rate of synthesis and 
the rate of degradation, both of which can be modulated by a number of factors, such as cytokines. 
These factors can be evoked by stimuli such as trauma to the skin. When superimposed on the 
individual’s genetic background, an imbalance in the flux through these pathways can result in collagen 
accumulation manifesting as tissue fibrosis. Adapted from Uitto and Kouba, 2000.
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Breach Delivery: Increased Solute 
Uptake Points to a Defective Skin 
Barrier in Atopic Dermatitis
W.H. Irwin McLean1 and Peter R. Hull1
Evidence is now emerging for enhanced penetration of chemical solutes into 
uninvolved skin of atopic dermatitis patients. Along with the recent discovery 
of prevalent null mutations in the gene encoding filaggrin, a protein essential 
for stratum corneum formation, these data point to an innate epidermal-barrier 
defect in atopy.
Journal of Investigative Dermatology (2007) 127, 8–10. doi:10.1038/sj.jid.5700609
Atopic dermatitis (AD, “eczema”) 
has increased in prevalence in recent 
decades; it now affects 15%–20% of 
children in the developed world alone 
and affects all races to differing degrees. 
The disease is a classical complex trait 
— it is clearly highly heritable but with 
reduced penetrance, and there is strong 
evidence for environmental influences 
(Morar et al., 2006). Furthermore, the 
disease impacts on other areas of medi-
cine, as a high percentage of eczema 
patients develop a range of additional 
allergic conditions, including food aller-
gies, asthma, and rhinitis, often occur-
ring in a temporal “program” known as 
the atopic march (Spergel and Paller, 
2003). AD causes considerable mor-
bidity and significantly affects quality 
of life. This is particularly the case for 
severe AD persisting into adulthood. 
Establishing the contributing etiological 
factors for this complex disease — both 
genetic predisposing factors and envi-
ronmental trigger factors — is of para-
mount importance in the development 
of new, possibly more effective treat-
ments and/or preventative regimens. 
Given that the skin is inflamed within 
an AD lesion, there is an obvious immu-
nological component in the disease; 
however, recent evidence coming from 
both molecular genetics and functional 
analysis strongly suggests that a skin 
barrier defect is the necessary cause in a 
considerable proportion of atopy cases.
Although there is considerable func-
tional evidence for impaired skin bar-
rier function within active lesional skin 
of AD patients, as seen, for example, 
by increased trans-epidermal water 
loss, the situation has been less clear in 
studies of uninvolved skin, where the 
results have been somewhat contradic-
tory. Ivone Jakasa and colleagues in 
Amsterdam and Rome (2007) present 
conclusive, statistically significant evi-
dence for enhanced uptake of an entire 
series of polyethylene glycols, covering 
molecular weights in the range 150–
590 daltons, in non-lesional skin of AD 
patients. This result is further supported 
by recently published evidence from 
the same research group for enhanced 
uptake of sodium lauryl sulfate in non-
lesional AD skin, based on the use of 
similar methods (Jakasa et al., 2006). 
Genji Imokawa’s group and collabo-
rators in Japan, using a photoacoustic 
spectography system, showed enhanced 
penetration of both a lipophilic and 
a hydrophilic dye through clinically 
normal skin of AD patients as com-
pared with control subjects. In addi-
tion, they showed a significant correla-
tion between penetration rates for the 
hydrophilic dye and elevated IgE levels 
for patients with severe AD (Hata et al., 
2002). Together, these reports strongly 
support the hypothesis that patients with 
AD have an inherent skin barrier defect, 
probably due to one or a combination 
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